Study: Ginseng as a remedy for chemical fatigue

Veröffentlicht:

Aktualisiert:

Von:

In dieser Studie wurde untersucht, ob die Einnahme von amerikanischem Ginseng (Panax quinquefolius) die Müdigkeit bei Krebspatienten, die unter krebsbedingter Müdigkeit (CRF) litten, verbessern kann. Es handelte sich um eine randomisierte, doppelblinde Studie, an der erwachsene Krebspatienten teilnahmen. Die Teilnehmer erhielten entweder 2.000 mg Ginseng täglich oder ein Placebo. Der primäre Endpunkt war die Veränderung der Müdigkeit nach 4 Wochen. Nach 8 Wochen wurde ein signifikanter Unterschied in der Ginseng-Gruppe festgestellt. Die Studie zeigte, dass die Einnahme von Ginseng bei Krebspatienten zu einer Verbesserung der Müdigkeit führen kann. Weitere Studien sind jedoch erforderlich, um die Langzeitwirkungen und die Sicherheit der …
In this study, it was examined whether the taking of American ginseng (Panax Quinquefolius) can improve the fatigue in cancer patients that suffered from cancer -related fatigue (CRF). It was a randomized, double -blind study in which adult cancer patients took part. The participants received either 2,000 mg ginseng daily or a placebo. The primary endpoint was the change in fatigue after 4 weeks. After 8 weeks, a significant difference was found in the Ginseng Group. The study showed that taking Ginseng in cancer patients can lead to an improvement in tiredness. However, further studies are necessary to the long -term effects and the safety of ... (Symbolbild/natur.wiki)

In this study, it was examined whether the taking of American ginseng (Panax Quinquefolius) can improve the tiredness of cancer patients that suffered from cancer -related fatigue (CRF). It was a randomized, double -blind study in which adult cancer patients took part. The participants received either 2,000 mg ginseng daily or a placebo. The primary endpoint was the change in fatigue after 4 weeks. After 8 weeks, a significant difference was found in the Ginseng Group. The study showed that taking Ginseng in cancer patients can lead to an improvement in tiredness. However, further studies are necessary to confirm the long -term effects and the safety of using Ginseng in cancer patients.

Details of the study:

Reference

Barton DL, Liu H, Dakhil SR, et al. Wisconsin-Ginseng ( Panax Quinquefolius ) To improve cancer-related fatigue: a randomized, double-blind study. J Natl Cancer Inst . August 21, 2013; 105 (16): 1230-1238.

Design

In a double -blind study, cancer patients received 2,000 mg Panax Quinquefolius (American ginseng or ginseng from Wisconsin) compared to placebo against cancer -related tiredness (CRF).

participant

Adult cancer patients who had undergone or completed them and suffered from fatigue, which was rated at least 4 on a numerical analog fatigue scale (1–10) at least 4. The exclusion criteria included any malignant diseases of the brain, the prior use of ginseng or the chronic intake of systemic steroids or opioids. Other causes of fatigue, such as pain and insomnia, were also examined and excluded. For all participants, the diagnosis was made within two years after the study enrollment. Three hundred and sixty participants (183 in the Ginseng Group, 181 in the placebo group) were enrolled from 40 institutions, and 200 participants were available for primary endpoint analysis (147 in the Ginseng Group, 153 in the placebo group).

study medication and dosage

The participants took two 500 mg capsules pure pure a panax quinquefolius rooted root from a production hinge or a suitable placebo with rice powder. The ginseng contained 3 % ginsenoside and was evaluated by an independent company for quality and effectiveness.

target parameter

The primary endpoint was the change in the general subscala of multidimensional fatigue symptom inventory (mfsi) from the starting value to 4 weeks. Other MFSI sub-scales and the Fatigue intertia-sub-scale of the Profile of Mood States (POMS) were also analyzed. The Data was converted to a scale of 0–100 and evaluated after 4 and 8 weeks. In a sub -quantity analysis, those who are currently being treated were analyzed compared to those with whom this was not the case. The toxicities were evaluated by self -disclosure and the provider evaluation according to the Common Terminology Criteria for Adverse Events (CTCAE) of the National Cancer Institute.

most important knowledge

Overall, there was no statistically significant difference in the MfSI values ​​after 4 weeks, but after 8 weeks a statistically significant difference could be observed for the ginseng group ( p = 0.003). For participants who underwent active treatment, there was a statistically significant improvement in tiredness both 4 and 8 weeks. According to self-assessment and ctcae classification, the toxicities did not differ significantly between the poor.

effects on practice

Interest in the use of Ginseng at CNI has increased since these research results were first presented at the annual conference of the American Society of Clinical Oncology in 2012. This attention is justified in view of the persistent and weakening nature of CNI and the lack of effective pharmacological interventions.

In accordance with the great cause (Latin for "eliminating the cause"), the uniqueness of CNI is to be clarified compared to ordinary fatigue. CNI is not alleviated by sleep or calm, 1 and patients with CNI report that they are "unusual or overwhelming tired". 2 chronic tiredness after treatment will tend to be stable over time, whereas the treatment -related fatigue during therapy. Better. 3 reports that the prevalence of fatigue in patients who undergo chemotherapy is between 59 % and 96 %, in patients who receive radiation therapy, 65 % to 100 % and for long -term survivors at 30 %. Corticosteroids, anabolic steroids, antidepressants and modafanil as well as L-carnitine and coenzyme Q10 used. However, only a few of these active ingredients were examined in large, placebo -controlled studies, and on the basis of preclinical data, none of the active ingredients examined has proven to be significantly helpful. Because of my experience in an integrative care environment, I largely agree that these treatments hardly change the energy.

The positive results of this study are convincing, especially in view of the broad spectrum of cancer patients.

aggravating that CRF's etiology is multifactorial and is largely misunderstood. The proposed mechanisms include inflammatory cytokines, 5 Dysregulation of the hypothalamus-hypophyses-nine-native axis (HPA), 6 Desynchronization of the circadian rhythm, 7 skeletal muscles, 8 and genetic dysregulation. 9 The advantage of using plant substances in this type of symptoms is that they contain a variety of components with different effects, many, such as Z Panax SPP , are immune modulators. Therefore, p. Quinquefolius can be able to positively influence individual cases of CNI with different combinations of causal factors. A large part of the research uses Panax SPP the entire amount of ginsenoside as well as the ginsenoside subtypes as important determinants of the result. The current study was designed for the use of 2,000 mg/day based on a pilot study from 2010 for CRF, in which escalating doses of p. Quinquefolius . In the pilot study (n = 290), the harvested harvest contained 5 % ginsenoside, and both the dosage of 1,000 mg and 2,000 mg/day showed a significantly improved fatigue over a period of 8 weeks compared to 750 mg/day. Placebo. In the study examined, the harvest contained 3 % ginsenoside.

The positive results of this study are convincing, especially in view of the broad cross -section of the participating cancer patients from 40 different locations, with 78 % of the participants completing all study interventions. Particularly noteworthy should be found that under current treatment, patients not only benefited from Ginseng after 4 weeks, but also improved over the period of 8 weeks. As already mentioned, patients with CRF are typically deteriorating this disease during therapy in patients with CRF. Therefore, one could think about the use p. Quinquefolius at the beginning of the therapy to prevent the occurrence of the symptom or at least to weaken its intensity.

This questions the security of the use of American ginseng during the treatment of patients. There is literature about the possible estrogen -potentive effect of p. Quinquefolius This leads to the spread of hormone -sensitive types of cancer. 11 It is not clear whether this is a valid effect of P. Quinquefolius. A 2006 study is intended to explain this finding how the ginseng is won. The researchers found that ginseng products that are not obtained from methanol extraction methods, but from water extraction or pure ground root have no estrogenic properties. occupy insensitive cell lines. 13

Another security risk is how the herb is metabolized by the liver. We do not want an intervention to be reduced or increased the metabolic rate of a chemotherapeutic agency. So far, in vitro data indicates a non-inhibiting effect of American ginseng on CP450 3A4. 14 CYP2B1, CYP3A23 and CYP1A2 gene expression. Overdose of medication. This represents a considerable risk, since the therapeutic window of chemotherapeutic agents tends to be very tight.

Since I am in the heart of herbalist, I have to show them the greatest respect p. Quinquefolius as a wild, local plant, which is traditionally used by both the eclectrics and the American indigenous people as a strength of the nervous system. It occurs wild from Canada to Georgia and is considered endangered. 16 The future livelihood of the wild American ginseng is at risk for several reasons, including over -harvested, the fact that it takes at least five years for the roots to grow before they are harvested, and increased economic incentives, since the price for wild roots continues to increase. As a result, commercial agricultural companies grow grain. In the future, researchers should always indicate the source of their crop and the specific subtypes of ginsenosides in the plant used, since there are differences between the crops grown in different bior regions.

The use of American ginseng as a potential prevention and treatment of CRF looks promising, but further research is required, since studies on humans demonstrate its security when using various chemotherapy drugs. It would also be worthwhile to investigate the effectiveness of American ginseng compared to other adaptogenic plants, such as z Eleutherococcus (Siberian ginseng) or Panax-Ginseng (Asian ginseng) in separate arms for evaluating the effectiveness and security in the treatment of patients with CNI.